Non-alcoholic fatty liver disease: Further expression of the metabolic syndrome

被引：206

作者：

Tarantino, Giovanni ^{[1
]}

Saldalamacchia, Gennaro ^{[1
]}

Conca, Paolo ^{[1
]}

Arena, Adriano ^{[1
]}

机构：

[1] Univ Naples Federico II, Sch Med, Dept Clin & Expt Med, I-80131 Naples, Italy

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2007年 / 22卷 / 03期

关键词：

non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; insulin resistance; metabolic syndrome; obesity;

D O I：

10.1111/j.1440-1746.2007.04824.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Non-alcoholic fatty liver disease has been associated with metabolic disorders, including central obesity, dyslipidema, hypertension and hyperglycemia. Metabolic syndrome, obesity, and insulin resistance are major risk factors in the pathogenesis of non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease refers to a wide spectrum of liver damage, ranging from simple steatosis to non-alcoholic steatohepatitis, advanced fibrosis and cirrhosis.

引用

收藏

页码：293 / 303

页数：11

相关论文

共 109 条

[1]

Glutamine supplementation of parenteral nutrition does not improve intestinal permeability, nitrogen balance, or outcome in newborns and infants undergoing digestive-tract surgery - Results from a double-blind, randomized, controlled trial [J].

Albers, MJIJ ;

Steyerberg, EW ;

Hazebroek, FWJ ;

Mourik, M ;

Borsboom, GJJM ;

Rietveld, T ;

Huijmans, JGM ;

Tibboel, D .

ANNALS OF SURGERY, 2005, 241 (04) :599-606

[2]

Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells [J].

Aleffi, S ;

Petrai, I ;

Bertolani, C ;

Parola, M ;

Colombatto, S ;

Novo, E ;

Vizzutti, F ;

Anania, FA ;

Milani, S ;

Rombouts, K ;

Laffi, G ;

Pinzani, M ;

Marra, F .

HEPATOLOGY, 2005, 42 (06) :1339-1348

[3]

ALHABSI KR, 2006, SMALL RUMINANT RES, V66, P244

[4]

Other disease associations with non-alcoholic fatty liver disease (NAFLD) [J].

Allard, JP .

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) :783-795

[5]

Current best treatment for nonalcoholic fatty liver disease [J].

Angulo, P .

EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) :611-623

[6]

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [J].

Arioglu, E ;

Duncan-Morin, J ;

Sebring, N ;

Rother, KI ;

Gottlieb, N ;

Lieberman, J ;

Herion, D ;

Kleiner, DE ;

Reynolds, J ;

Premkumar, A ;

Sumner, AE ;

Hoofnagle, J ;

Reitman, ML ;

Taylor, SI .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :263-274

[7]

Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome [J].

Baillargeon, JP ;

Iuorno, MJ ;

Jakubowicz, DJ ;

Apridonidze, T ;

He, N ;

Nestler, JE .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :242-249

[8]

Fat-containing lesions of the liver: Cross-sectional imaging findings with emphasis on MRI [J].

Basaran, C ;

Karcaaltincaba, M ;

Akata, D ;

Karabulut, N ;

Akinci, D ;

Ozmen, M ;

Akhan, O .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (04) :1103-1110

[9]

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [J].

Basaranoglu, M ;

Acbay, O ;

Sonsuz, A .

JOURNAL OF HEPATOLOGY, 1999, 31 (02) :384-384

[10]

Bastarolo Desiree, 2005, Ital Heart J Suppl, V6, P382

← 1 2 3 4 5 6 7 8 9 10 →